Sugi Predict

Sugi Predict / Compounds / SCHEMBL19207619

SCHEMBL19207619

SCHEMBL19207619

O=C(O)c1nnc(Cc2ccccc2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.56
▸ ALDH1A1 P00352 2/20 0.56
▸ FFAR1 O14842 1/20 0.56
▸ KMT2A Q03164 3/20 0.55
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ MEN1 O00255 2/20 0.55
▸ ABL1 P00519 2/20 0.54
▸ POLB P06746 2/20 0.54
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.49
▸ LMNA P02545 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ HDAC6 Q9UBN7 1/20 0.48
▸ THRB P10828 1/20 0.47
▸ APEX1 P27695 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319595 0.84 ATM (0.57) ALDH1A1KMT2ANPC1RAB9AMEN1
SCHEMBL22272749 0.82 POLB (0.62) TSHRALDH1A1FFAR1KMT2ANPC1
SCHEMBL19207884 0.80 KMT2A (0.52) TSHRALDH1A1FFAR1KMT2ANPC1
SCHEMBL24991273 0.80 GLS (0.47) FFAR1LMNA
SCHEMBL31201618 0.77 ALDH1A1 (0.63) TSHRALDH1A1FFAR1KMT2ANPC1
SCHEMBL2644442 0.72 ALDH1A1 (1.00) TSHRALDH1A1KMT2ANPC1RAB9A
SCHEMBL8840161 0.72 NPC1 (0.51) ALDH1A1KMT2ANPC1RAB9AMEN1
SCHEMBL28060950 0.72 ALDH1A1 (0.61) TSHRALDH1A1KMT2ANPC1RAB9A
SCHEMBL2211930 0.72 ALDH1A1 (0.61) TSHRALDH1A1KMT2ANPC1RAB9A
SCHEMBL12993518 0.72 HDAC6 (0.63) TSHRALDH1A1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388601-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2025-12-25 — — US disclosed
US-12358928-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2025-07-15 — — US disclosed
CN-118994191-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-118994190-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-11-22 — — CN disclosed
CN-114437105-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2024-10-11 — — CN disclosed
US-20240150376-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2024-05-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
US-20230043400-A1 Compounds, Compositions and Methods DENALI THERAPEUTICS INC. (US) 2023-02-09 — — US disclosed
CN-114437105-A Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-05-06 — — CN disclosed
CN-109071504-B Inhibitors of receptor interacting protein kinase 1 戴纳立制药公司 2022-03-08 — — CN disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2018-01-25 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
US-9815850-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2017-11-14 — — US disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
WO-2017136727-A2 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2017-08-10 — — WO disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2017-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388601-A1 Compounds, Compositions and Methods AURKC, WEE2, ERBB2 TSHR 1074/4885ALDH1A1 3854/4885FFAR1 1414/4885
US-20240150376-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB TSHR 4584/4885ALDH1A1 4405/4885FFAR1 3199/4885
US-12358928-B2 Compounds, compositions and methods PIK3CA, PLK1, PIK3CB TSHR 4584/4885ALDH1A1 4405/4885FFAR1 3199/4885
US-20230043400-A1 Compounds, Compositions and Methods PIK3CA, PLK1, PIK3CB TSHR 4584/4885ALDH1A1 4405/4885FFAR1 3199/4885
US-20180022759-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB TSHR 4584/4885ALDH1A1 4405/4885FFAR1 3199/4885
US-20170226127-A1 COMPOUNDS, COMPOSITIONS AND METHODS PIK3CA, PLK1, PIK3CB TSHR 4584/4885ALDH1A1 4405/4885FFAR1 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.